Sirolimus and athlete drug testing: is it banned?

Last updated 2026-07-27

Is sirolimus (rapamycin) on WADA's Prohibited List?

As of the current published list, sirolimus is not named on the World Anti-Doping Agency's Prohibited List. WADA publishes an updated List every year, effective January 1, and it is a mistake to assume this year's absence means next year's absence ^[1]. The List works by naming specific substances and classes: anabolic agents, hormones, beta-2 agonists, diuretics, and so on. Sirolimus is an mTOR inhibitor, a completely different mechanism than anabolic steroids or growth hormone, and it doesn't fit neatly into the categories WADA has historically targeted. That's likely why it hasn't shown up. It is not evidence that WADA has reviewed it and decided it's fine. Everolimus, a close chemical relative of sirolimus (both are rapalogs, both hit mTOR), is also absent from the list. So this isn't a sirolimus-specific gap, it's that the mTOR inhibitor class as a whole hasn't been a doping enforcement priority. That could change if evidence emerges that athletes are using these drugs for performance or recovery benefit. WADA's list is a legal instrument adopted by signatory countries and sport federations under the World Anti-Doping Code, not a static registry, and it is amended based on evidence of "performance-enhancing potential," "health risk," and violation of the "spirit of sport" ^[1][2]. All three criteria matter here, and mTOR inhibition touches on more than one of them.

Could sirolimus become a banned substance in the future?

It's plausible, though nothing has been announced. WADA adds substances to the Prohibited List when at least two of three criteria are met: potential to enhance performance, potential health risk to athletes, and violation of the spirit of sport ^[2]. Rapamycin's mouse lifespan and health-span data, run through the National Institute on Aging's Interventions Testing Program (ITP), is genuinely strong, and that data has fueled a growing off-label longevity and recovery-focused user base among non-elite adults ^[3]. Whether that translates into any real athletic performance benefit (faster recovery, reduced inflammation, altered muscle protein synthesis via mTOR pathway modulation) is unproven in competitive athletes. There is no completed human trial showing rapamycin improves athletic performance, recovery time, or competitive outcomes in healthy people of any age. The interest in rapamycin among athletes, to the extent it exists, appears driven by longevity and recovery narratives circulating in ITP-derived rodent data, not by controlled human sport-science trials. WADA does track compounds with a plausible performance rationale even before evidence solidifies. If rapamycin's off-label recreational and performance use grows, and if any data (even weak, self-reported data) suggests athletes are using it to blunt inflammation or accelerate recovery between training blocks, it becomes a more obvious candidate for future review. Athletes should not bet on permanent absence from the list.

Why is sirolimus immunosuppressive, and does that matter for athletes?

Sirolimus is FDA-approved as an immunosuppressant to prevent organ transplant rejection, marketed since 1999 under the brand name Rapamune, and it works by inhibiting mTOR (mechanistic target of rapamycin), a protein central to cell growth and immune cell proliferation ^[4]. This is not a side effect, it is the drug's core approved mechanism. For an athlete, immunosuppression is a real practical problem independent of any doping rule. Suppressed immune function means slower recovery from minor infections, elevated risk from training-related tissue damage becoming infected, and potentially blunted training adaptations if the drug is taken continuously and dampens the inflammatory signaling that drives some exercise adaptations. Continuous, transplant-style daily dosing is well documented to increase infection risk. The off-label longevity community has moved toward intermittent, once-weekly or twice-weekly dosing specifically to reduce this exposure, though even that pattern hasn't been tested in trials for infection risk in healthy athletic populations ^[5]. Sirolimus and rapamycin are the same molecule (sirolimus is the generic/USAN name, rapamycin is the original name derived from Rapa Nui, Easter Island, where the source bacterium was found). Anyone reading both terms in fitness or longevity forums should know they're not looking at two different drugs. Athletes considering it off-label are taking on an FDA-approved immunosuppressant's real biological risk profile for a benefit (performance or longevity) that has not been demonstrated in human trials of any kind, let alone in competitive athletes specifically.

What are the real side effects athletes should worry about?

Beyond immunosuppression, three effects come up constantly in both the FDA prescribing information and the off-label longevity literature: mouth ulcers (stomatitis), metabolic disturbance, and lipid changes. Mouth ulcers (aphthous stomatitis) are one of the most commonly reported adverse effects in sirolimus clinical trials, described in the FDA label for Rapamune as a frequent adverse reaction across dose ranges studied in transplant patients ^[6]. In the off-label longevity community, intermittent weekly dosing is partly an attempt to reduce this and other cumulative side effects, though there's no controlled trial confirming that intermittent dosing eliminates the risk in otherwise healthy people. Metabolic effects matter especially for athletes. Sirolimus can raise blood glucose, worsen insulin sensitivity, and elevate triglycerides and LDL cholesterol. These effects are documented in the FDA label and in transplant literature where sirolimus-based regimens show higher rates of new-onset diabetes and dyslipidemia compared to some alternative immunosuppressants ^[6]. For an athlete relying on stable metabolic function for training and competition, unpredictable glucose or lipid shifts are a real performance and health cost, not a theoretical one. Other documented effects include delayed wound healing, elevated blood pressure, and low platelet or white blood cell counts in some patients ^[6]. None of these were studied in healthy, competitive athletes. All of the safety data comes from sick transplant patients or, for longevity dosing, from small observational cohorts and case series, not randomized controlled trials in athletic populations. Anyone weighing this should look closely at Sirolimus Rx dosage protocols and understand that off-label dosing schedules are extrapolated from limited human pharmacokinetic data, not sport-specific trials.

Is there any human trial evidence that rapamycin helps athletic performance or recovery?

No. There is no completed randomized controlled trial showing rapamycin improves athletic performance, endurance, strength recovery, or injury healing in healthy competitive athletes. This is the central gap in the entire rapamycin longevity conversation, and it applies with equal force to athletic claims. The strongest evidence for rapamycin extending lifespan and improving certain healthspan markers comes from the NIA's Interventions Testing Program, a multi-site mouse study that has repeatedly found rapamycin extends median and maximum lifespan in genetically heterogeneous mice, including when started relatively late in life ^[3][7]. That is a strong, replicated finding in mice. It is not a human finding, and it says nothing directly about muscle recovery, VO2 max, tendon healing, or any metric that matters to a competitive athlete. A small number of human studies (short-duration, low-dose, small sample sizes) have looked at immune function markers or general safety in healthy older adults, none of them designed around or powered for athletic performance outcomes . Nobody has run the trial that would actually answer whether rapamycin helps an athlete recover faster or perform better. Anyone telling an athlete it will is extrapolating from mouse biology and small non-athletic human safety studies, not from evidence that answers the question being asked.

Could sirolimus show up on a routine drug test even though it isn't banned?

Yes, technically, if the testing lab happens to screen for it or if it's flagged incidentally, but this is not how standard anti-doping testing works in practice. WADA-accredited labs test specifically for substances and methods on the Prohibited List using targeted assays. They are not running an open-ended toxicology screen for every drug in a sample ^[1]. That said, professional sports leagues and some employers run broader drug panels for other reasons (workplace safety, insurance, league-specific policy) that can differ from WADA's list. An athlete under a league-specific substance policy, rather than pure WADA jurisdiction, should check that specific policy rather than assume WADA's list is the only relevant standard. College athletes under NCAA rules face a separate list that also does not currently name sirolimus specifically, but again, separate list, separate review cycle, separate risk of future addition. The practical answer: a positive detection of sirolimus in a WADA-governed test today would not itself constitute an anti-doping rule violation, because it isn't a prohibited substance. But an athlete under any testing regime should disclose all medications and supplements to their team physician or sport's medical staff regardless of prohibited status, both for health monitoring (given the metabolic and immune effects above) and because prohibited-list status can change year to year.

Why would an athlete even consider off-label rapamycin?

The interest traces almost entirely to the mouse longevity data, not to any athletic performance rationale established in humans. The NIA's ITP has found rapamycin extends lifespan in mice fed the drug starting in middle age, with effects seen across multiple independent test sites and both sexes, one of the most replicated findings in the aging-biology research world ^[3][7]. That data has generated a large off-label adult user base seeking general healthspan benefits: better recovery from minor injuries, reduced inflammation, potential protection against age-related decline. Some of this crosses into athletic and fitness communities because "faster recovery" and "lower inflammation" sound like exactly what an athlete wants. The extrapolation from 24-month-old mice to a 30-year-old competitive athlete is large, and it has not been tested. For a masters athlete or an aging former competitor thinking about long-term healthspan rather than competitive-season performance, the calculus is different than for a currently competing, tested athlete. The former is making a personal off-label medical decision with a physician, weighing real mouse data against real human risk data from transplant medicine, discussed in more depth on Sirolimus Rx dosage and Sirolimus Rx cycle length. The latter, a tested competitive athlete, is taking on an unresolved future doping-list risk on top of the health risk, for a performance benefit nobody has shown exists.

How does off-label intermittent dosing usually work, and does that change the risk profile?

Most off-label longevity protocols use once-weekly or twice-weekly dosing rather than the daily dosing studied in transplant patients, on the theory that intermittent, pulsed mTOR inhibition captures benefit while giving the immune system recovery time between doses ^[5]. Typical off-label doses discussed in this community range from about 2 mg to 8 mg once weekly, substantially different from the continuous daily regimens (with loading doses) used in transplant medicine ^[6]. This is a genuinely different pharmacological approach than what the FDA safety data was built on. The theoretical rationale (peak-and-trough dosing preserving some mTORC1 inhibition benefit while limiting mTORC2 inhibition, which is thought to drive some of the metabolic and immune side effects) has support in some animal and mechanistic studies, but there is no large human trial confirming that intermittent dosing meaningfully reduces the real-world rates of infection, mouth ulcers, or metabolic disturbance compared to daily dosing ^[5]. Anyone starting this kind of protocol needs baseline and follow-up labs (lipid panel, fasting glucose or HbA1c, complete blood count, kidney function) and a physician who understands both the transplant literature and the emerging off-label longevity literature. Details on reconstitution, injection technique, and site rotation, relevant because compounded formulations require careful handling, are covered in how to reconstitute Sirolimus Rx, Sirolimus Rx how to inject, and Sirolimus Rx injection sites, though oral tablet or solution dosing is more common than injection in most protocols. Confirm your specific formulation and route with your prescriber.

What should a competitive athlete actually do before using sirolimus?

Talk to a physician who knows the athlete's specific sport, testing jurisdiction (WADA, NCAA, a professional league's own policy), and full medical history before starting anything. This isn't a formality. It's the only way to get an answer that accounts for a fast-moving prohibited list and a drug with real, documented metabolic and immune effects. Check the current year's list directly rather than relying on last year's status or a forum post. WADA publishes the list annually and it takes effect January 1 each year, with the current and previous versions posted publicly ^[1]. A substance's absence in one year's list is not a guarantee for the next. Get baseline labs before starting and repeat them on a schedule. Lipid panel, glucose or HbA1c, complete blood count, and kidney function are the minimum given sirolimus's documented effects on all four ^[6]. Report the medication to team medical staff regardless of prohibited status, since health monitoring matters independent of anti-doping rules, and because undisclosed medication use complicates care if a side effect does show up mid-season. For competitive athletes under active testing, the honest recommendation is caution bordering on avoidance: the performance benefit is unproven in humans, the health risks are real and documented, and the regulatory status could change with no warning. For non-competing adults interested in the longevity rationale, working through a provider-reviewed path (like the one Sirolimus Rx connects patients to, with prescriptions filled through a licensed pharmacy partner) at least ensures medical oversight and lab monitoring, which off-label self-sourcing often skips entirely.

Frequently asked questions

Is rapamycin the same drug as sirolimus?

Yes. Sirolimus is the generic (USAN) name; rapamycin is the original name from the compound's discovery in a soil bacterium on Rapa Nui (Easter Island). Same molecule, same FDA-approved drug (brand name Rapamune), used interchangeably in medical and longevity literature.

Is sirolimus banned by WADA?

Not currently. Sirolimus does not appear on WADA's published Prohibited List as of the most recent version. That could change; WADA updates the list annually effective each January 1, adding substances based on performance-enhancing potential, health risk, and spirit-of-sport criteria.

Can sirolimus improve athletic recovery or performance?

There's no completed human trial showing this. The strong evidence for rapamycin is lifespan extension in mice from the NIA's Interventions Testing Program. Nobody has run a controlled study in competitive athletes measuring recovery time, strength, or endurance outcomes.

Why do people take rapamycin off-label if it's not for athletes?

Interest stems from mouse longevity data, not athletic performance trials. Some users hope general anti-inflammatory or metabolic effects translate to better recovery, but that's extrapolation from rodent aging studies and small non-athletic human safety studies, not evidence specific to sport.

Does sirolimus suppress the immune system?

Yes. It's FDA-approved specifically as an immunosuppressant to prevent transplant organ rejection, working by inhibiting mTOR, a protein central to immune cell proliferation. This is its core mechanism, not a side effect, and it applies at any dose level, though continuous dosing carries higher infection risk than intermittent dosing.

What are the most common side effects of sirolimus?

Mouth ulcers (stomatitis), elevated blood glucose, elevated triglycerides and LDL cholesterol, delayed wound healing, and low blood cell counts are all documented in the FDA prescribing information for Rapamune, based on transplant patient trials rather than healthy-athlete populations.

Would a routine drug test flag sirolimus?

WADA-accredited labs test for substances on the Prohibited List using targeted assays; since sirolimus isn't listed, a standard anti-doping test wouldn't flag it as a violation even if detected. League-specific or workplace drug panels may differ, so check your specific jurisdiction's policy.

Is sirolimus approved by the FDA for longevity or anti-aging use?

No. Sirolimus is FDA-approved only for transplant rejection prevention, and related formulations (Fyarro, Hyftor) for specific cancer and skin conditions. Any use for longevity, healthspan, or athletic performance is entirely off-label and unapproved by the FDA.

How is off-label rapamycin dosed differently than the FDA-approved use?

FDA-approved transplant dosing is daily, often with a loading dose. Off-label longevity protocols typically use intermittent dosing, commonly once weekly, at doses around 2 to 8 mg, based on the theory that pulsed dosing reduces cumulative side effects, though this hasn't been confirmed in large human trials.

Could rapamycin be added to WADA's banned list in the future?

It's possible. WADA adds substances meeting at least two of three criteria: performance enhancement potential, health risk, and spirit-of-sport violation. Growing off-label use and recovery-related claims could prompt future review, so absence from today's list is not a permanent guarantee.

What labs should someone get before starting sirolimus off-label?

A baseline and periodic lipid panel, fasting glucose or HbA1c, complete blood count, and kidney function test, given sirolimus's documented effects on all four in FDA and transplant literature. A prescribing physician should order and interpret these, not a self-directed protocol.

Is there a human lifespan trial for rapamycin?

No completed human lifespan trial exists. The mouse lifespan data from the NIA's Interventions Testing Program is strong and repeatedly replicated, but no randomized controlled trial has measured rapamycin's effect on human lifespan or aging outcomes to date.

Sources

1. World Anti-Doping Agency, Prohibited List: WADA publishes an annually updated Prohibited List effective January 1; sirolimus does not currently appear on it
2. World Anti-Doping Agency, World Anti-Doping Code: Criteria for adding a substance to the Prohibited List: performance-enhancing potential, health risk, and violation of the spirit of sport
3. National Institute on Aging, Interventions Testing Program: The NIA's ITP has found rapamycin extends lifespan in genetically heterogeneous mice across multiple test sites
4. Mannick et al., Science Translational Medicine (2018): Intermittent low-dose mTOR inhibitor dosing has been studied for immune function effects in older adults, distinct from continuous transplant dosing
5. Harrison et al., Nature (2009): Rapamycin extends median and maximum lifespan in mice even when treatment began at 600 days of age
6. Kraig et al., Experimental Gerontology (2018): Small human studies of low-dose rapamycin in older adults have examined safety and immune markers, not athletic performance outcomes
7. PubMed, sirolimus intermittent dosing pharmacokinetics literature: Off-label intermittent weekly dosing regimens are based on pharmacokinetic and mechanistic rationale distinct from daily transplant regimens